BLCM News and Press, Bellicum Pharmaceuticals Inc. From 09/01/21

Gainers: ABVC BioPharma (NASDAQ:ABVC) +32%, Bellicum Pharmaceuticals (NASDAQ:BLCM) +22%, Evaxion Biotech (NASDAQ:EVAX) +22%, GBS (NASDAQ:GBS) +22%, PetVivo (NASDAQ:PETV) +17%. Losers: Avidity Biosciences (NASDAQ:RNA) -18%, So-Young (...

GBS (NASDAQ:GBS) +51%. Anaplan PLAN +17% on Q2 earnings. Bellicum Pharmaceuticals (NASDAQ:BLCM) +16% and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch Skillz  (NYSE:SKLZ) +11%. Conn's CONN +11% on Q2 earnings. PVH PVH&...

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc . (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement cov...

- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe ® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in patients with previousl...

Bellicum Pharmaceuticals ([[BLCM]] +3.0%) has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center and Massachusetts General Hospital.The agreement covers certain intellectual property and technology rights regarding the company&#x...

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Ca...

At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...

Bellicum Pharmaceuticals (BLCM): Q1 GAAP EPS of -$1.12 beats by $0.25.Cash and cash equivalents and restricted cash of $29.6M. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements into the second quarter of 2022.Press...

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. “In the firs...

Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bellicum was only a few quarters away from being a commercial company and collecting rev...